The FTSE 100 has reached new heights in 2026, yet many high-quality UK stocks continue to be undervalued. Several leading companies on the London stock market have experienced significant declines over the past year, prompting a closer examination of potential investment opportunities. While some stock price drops correlate with understandable factors, others appear disproportionate.
In particular, three FTSE 250 companies stand out as surprisingly cheap, presenting a compelling case for investors.
Softcat has seen its shares drop markedly since last summer, with a forward price-to-earnings (P/E) ratio now standing at 19.6. Although this figure might not seem low in isolation, it is notably lower when compared to the European IT sector’s average P/E of 34 to 35. Though companies have generally paused tech spending, Softcat reports impressive growth, achieving double-digit profit increases for the twentieth consecutive year as of June. Given the firm’s expertise across various burgeoning technology trends, it is expected to continue outperforming its peers, contributing to the decision of some investors to open positions in Softcat.
Market analysts are largely optimistic about Softcat’s prospects; among 13 analysts assessing the stock, nine have rated it a “Strong Buy,” while three suggest holding and only one has advised selling.
Ibstock, the UK’s largest brick manufacturer by volume, has also faced a sharp decline in share price amid waning optimism about sustained improvements in housebuilding. However, recent key housing data indicates a potential rebound, with the possibility of accelerated market activity as interest rates decrease and planning regulations are eased. Currently, Ibstock’s price-to-earnings-to-growth (PEG) ratio stands at 0.5, suggesting the company is trading below its intrinsic value.
Though market sentiment is mixed, with four of ten analysts rating the company as a “Buy” and the remainder categorizing it as a “Hold,” its current pricing warrants serious attention from discerning investors.
Spire Healthcare, a major player in the UK private hospital sector, saw a significant drop in shares last December due to reduced NHS-related work linked to government budgetary constraints. Nevertheless, the stock has begun to rebound in 2026, buoyed by increasing demand from self-paying patients as NHS waiting lists continue to grow. Even if current rumors about a takeover do not materialize, the company is well-positioned to enhance profitability and share value.
Analysts are unanimously positive about Spire, with six analysts currently rating the stock—five with a “Strong Buy” and one with a standard “Buy” rating. The company’s PEG ratio for 2026 is an attractive 0.4.
In summary, while the potential exists for further declines in these UK stocks, current valuations suggest excellent opportunities for savvy investors. Each of these companies offers significant value at present, deserving of careful consideration.
